BIOSPECIFICS TECHNOLOGIES CORP Form 8-K February 03, 2010

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 2, 2010

# BIOSPECIFICS TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

**Delaware** (State or Other Jurisdiction Of Incorporation)

0-19879

(Commission File Number)

11-3054851

(I.R.S. Employer Identification No.)

35 Wilbur Street Lynbrook, NY 11563

(Address of Principal Executive Office) (Zip Code)

#### 516.593.7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- O Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
- O Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- O Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

## Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

## INTRODUCTORY COMMENT

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technolog Corp.

#### **ITEM 8.01 OTHER EVENTS**

On February 2, 2010, the Company announced that the U.S. Food and Drug Administration has approved XIAFLEX for the treatment of adult Dupuytren s contracture patients with a palpable cord.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

#### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

- (d) Exhibits
- 99.1 Press release dated February 2, 2010

## Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 3, 2010 BIOSPECIFICS TECHNOLOGIES CORP.

(Registrant)

/s/ Thomas L. Wegman

Thomas L. Wegman President

## Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

### **EXHIBIT INDEX**

**Exhibit** Description

No.

99.1 Press release dated February 2, 2010